Articles > Reference > News Wires, White Papers, and Books > Pharma Marketletter articles > July 2004

Article: Amdipharm gains UK rights for Detrunorm.(Brief Article)

Article from:
Pharma Marketletter
Article date:
July 26, 2004
Copyright

Amdipharm says it has obtained exclusive UK marketing rights for the overactive bladder therapy, Detrunorm (propiverine), from Germany-based Apogepha Arzneimittel GmbH. The agent was previously licensed to Schering-Plough in this market (Marketletters passim).

Under the terms of the accord, the UK firm will pay Apogepha an undisclosed single cash ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: Japan stock market week to Jan 22, 2007.(Statistical data)
Pharma Marketletter;  January 29, 2007 ;     700+ words ... ... at more than 700 sites in 30 countries. Nippon Shinyaku lost 0.2% because it terminated an agreement with APOGEPHA Arzneimittel GmbH of Germany for the development and marketing of NS-8 in the treatment of overactive bladder. The decision ...

Article: Nippon Shinyaku, Apogepha Terminate Development of NS-8, for the ...
JCNN News Summaries - Japan Corporate News Network;  January 25, 2007 ;     356 words ...Tokyo, Jan 25, 2007 - (JCN) - Nippon Shinyaku and Apogepha Arzneimittel GmbH announced on January 16 their decision toterminate an agreement for the development and marketing of NS-8, a novel compound ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives